Dr Kelly Paton
Research Officer, Laboratory Manager
Department of Microbiology and Immunology
14 Scholarly works
2 Projects
HIGHLIGHTS
2026
Research contracts (non-grants)
MTA for IL-15 Knockout Mice
2025
Journal article
Effects of Biased Analogues of the Kappa Opioid Receptor Agonist, U50,488, in Preclinical Models of Pain and Side Effects
DOI: 10.3390/molecules300306042024
Research contracts (non-grants)
Pilot Study to Test Feasibility of Spatial Transcriptomics Platforms on Available Human Tissue Samples.
2023
Journal article
KAPPA OPIOID RECEPTOR AGONISTS MODULATE THE ANTI-INFLAMMATORY ACTIONS OF MICROGLIA AND PROMOTE OLIGODENDROCYTE MATURATION AND MYELIN REPAIR IN PRECLINICAL MODELS OF MULTIPLE SCLEROSIS.
DOI: 10.1016/j.ibneur.2023.08.11742022
Journal article
Sex Differences in the Behavioural Aspects of the Cuprizone-Induced Demyelination Model in Mice
DOI: 10.3390/brainsci121216872022
Journal article
Sex Differences in Kappa Opioid Receptor Agonist Mediated Attenuation of Chemotherapy-Induced Neuropathic Pain in Mice
DOI: 10.3389/fphar.2022.8135622021
Journal article
The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis
DOI: 10.3389/fneur.2021.782190
RECENT SCHOLARLY WORKS
2021
Journal article
The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain
DOI: 10.1016/j.neuropharm.2020.1084452020
Journal article
N-docosahexaenoyl ethanolamine (synaptamide) has antinociceptive effects in male mice
DOI: 10.1002/ejp.16412020
Journal article
Strategies for developing k opioid receptor agonists for the treatment of pain with fewer side effects
DOI: 10.1124/JPET.120.0001342020
Journal article
Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
DOI: 10.3389/fnins.2020.007652019
Conference Proceedings
Therapeutic administration of the Salvinorin A analogue, EOM, enabled functional recovery and remyelination in two experimental models of multiple sclerosis